Answer
Wegovy (semaglutide) is indicated alongside a reduced-calorie diet and increased physical activity for weight loss and maintenance in adults with an initial BMI of at least 30 kg/m², or 27 to below 30 kg/m² with at least one weight-related comorbidity.
Sources for this answer
- Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled penNovo Nordisk Limited · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked